title: Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe?
abstract: OBJECTIVE
  The objective was to determine the composition of three available solutions of sodium tetradecyl sulfate from compounding pharmacies in comparison to pharmaceutical-grade sodium tetradecyl sulfate, Fibrovein (STD Pharmaceuticals, Ltd.).
  
  
  METHODS
  Solutions of 3% sodium tetradecyl sulfate were obtained from three compounding pharmacies. An analysis of their composition was performed.
  
  
  RESULTS
  All samples of 3% sodium tetradecyl sulfate obtained had a different concentration of sodium tetradecyl sulfate than that stated on the bottle (range, 2.59%-3.39%). Significant concentrations of the contaminant carbitol were present in samples from all three sources (0.33%-4.18%).
  
  
  CONCLUSIONS
  The production of 3% sodium tetradecyl sulfate by these three compounding pharmacies appears to occur by simple dilution of a 27% industrial detergent solution that is not manufactured for use in humans. Physicians need to be aware that the stated concentration may not be correct and that along with sodium tetradecyl sulfate, potentially harmful contaminants may be present in the solution.
authors.affiliation: La Jolla Spa MD, Dermatology/Cosmetic Laser Associates of La Jolla, Inc., La Jolla, California 92037, USA. MGoldman@SpaMD.com
authors.forename: Mitchel P
authors.initials: MP
authors.lastname: Goldman
mesh_terms: D002140:California; D004339:Drug Compounding / Q000592:standards*; D005026:Ethylene Glycols / Q000737:chemistry; D006801:Humans; D011785:Quality Assurance, Health Care; D012597:Sclerosing Solutions / Q000009:adverse effects / Q000737:chemistry*; D015911:Sclerotherapy / Q000009:adverse effects; D012981:Sodium Tetradecyl Sulfate / Q000009:adverse effects / Q000737:chemistry*; D014648:Varicose Veins / Q000628:therapy*
chemical_list: D005026:Ethylene Glycols; D012597:Sclerosing Solutions; C010111:carbitol; D012981:Sodium Tetradecyl Sulfate